Targeting protein kinase C subtypes in pancreatic cancer

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


In preclinical studies, protein kinase C (PKC) enzymes have been implicated in regulating many aspects of pancreatic cancer development and progression. However, clinical Phase I or Phase II trials with compounds targeting classical PKC isoforms were not successful. Recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. Members of these two subgroups converge signaling induced by mutant Kras, growth factors and inflammatory cytokines. Different approaches for the development of inhibitors for atypical PKC and novel PKC have been described; and new compounds include allosteric inhibitors and inhibitors that block ATP binding.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalExpert review of anticancer therapy
Issue number4
StatePublished - Apr 1 2015


  • inhibitor
  • pancreatic cancer
  • protein kinase C
  • therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Targeting protein kinase C subtypes in pancreatic cancer'. Together they form a unique fingerprint.

Cite this